Filing Details

Accession Number:
0000899243-23-011945
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-01 16:46:25
Reporting Period:
2023-04-27
Accepted Time:
2023-05-01 16:46:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1829360 S. David Ege C/O Seres Therapeutics, Inc.
200 Sidney Street
Cambridge MA 02139
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-04-27 20,000 $0.00 66,734 No 4 A Direct
Common Stock Disposition 2023-04-28 7,038 $5.19 59,696 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. On May 3, 2021, the reporting person was granted an award of 40,000 restricted stock units, which vested in the form of shares of the Issuer's common stock in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in the vesting and settlement of the award as to 20,000 shares.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 3, 2021, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.0350 to $5.1900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.